Roehrs T A, Roth T
Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI, USA; Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA.
Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI, USA; Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA.
Sleep Med. 2016 Jul;23:16-20. doi: 10.1016/j.sleep.2016.06.008. Epub 2016 Jul 6.
Given concerns about the abuse liability of hypnotics, this study assessed hyperarousal in people with insomnia and its relation to hypnotic self-administration over 12 months of nightly hypnotic use.
Ninety-five subjects with insomnia (age 32-64 years) underwent screening nocturnal polysomnogram (NPSG) and Multiple Sleep Latency Test (MSLT) the following day and, then, were randomized to receive zolpidem 10 mg or placebo nightly for 12 months. NPSGs and MSLTs were conducted and urine was collected (0700-1500 h) and analyzed for norepinephrine (NE) levels during months one and eight on study medication. A subset (n = 54) underwent hypnotic self-administration assessments in months one, four, and 12.
Mean daily sleep latency on screening MSLT was distributed across the full range of MSLT latencies (2-20 min). The highest screening MSLT latencies were detected in subjects with higher NE levels, compared to those with the lowest MSLT latencies. In the subset undergoing self-administration assessment, those with the highest MSLT latencies chose more capsules (placebo and zolpidem) and increased the number of capsules chosen in months four relative to month one, compared to those with the lowest MSLT latencies.
These data show that some insomniacs are hyperaroused with high MSLT/NE levels and, compared to low MSLT/NE insomniacs, they increase the number of capsules (zolpidem and placebo) self-administered on months four and 12 relative to Month one.
鉴于对催眠药物滥用可能性的担忧,本研究评估了失眠患者的高觉醒状态及其与连续12个月每晚使用催眠药物的自我给药之间的关系。
95名失眠患者(年龄32 - 64岁)接受了夜间多导睡眠图(NPSG)筛查,并于次日进行多次睡眠潜伏期测试(MSLT),然后被随机分为每晚服用10毫克唑吡坦或安慰剂,为期12个月。在研究用药的第1个月和第8个月进行NPSG和MSLT测试,并收集尿液(0700 - 1500时),分析去甲肾上腺素(NE)水平。一个亚组(n = 54)在第1、4和12个月接受了催眠药物自我给药评估。
筛查时MSLT的平均每日睡眠潜伏期分布在MSLT潜伏期的整个范围内(2 - 20分钟)。与MSLT潜伏期最短的受试者相比,NE水平较高的受试者检测到的筛查MSLT潜伏期最长。在接受自我给药评估的亚组中,与MSLT潜伏期最短的受试者相比,MSLT潜伏期最长的受试者选择了更多胶囊(安慰剂和唑吡坦),并且在第4个月相对于第1个月增加了所选胶囊的数量。
这些数据表明,一些失眠患者处于高觉醒状态,MSLT/NE水平较高,与低MSLT/NE水平的失眠患者相比,他们在第4个月和第12个月相对于第1个月自我给药的胶囊(唑吡坦和安慰剂)数量增加。